Sulodexide and glycosaminoglycans in the progression of renal disease

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Masola, Valentina ^a   Zaza, Gianluigi ^a   Gambaro, Giovanni ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

diabetic nephropathy; FGF 2; glycosaminoglycans; heparanase 1; sulodexide

Indexed keywords

DIABETIC NEPHROPATHY; FGF-2; GLYCOSAMINOGLYCANS; HEPARANASE-1; SULODEXIDE;

ANIMALS; ANTICOAGULANTS; DISEASE PROGRESSION; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY DISEASES;

GLYCOSAMINOGLYCAN; HEPARIN; SULODEXIDE;

ALBUMINURIA; ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL KIDNEY DISEASE; GLOMERULITIS; GLOMERULOPATHY; HUMAN; HYPOALBUMINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION;

EID: 84893822235     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft389     Document Type: Review

References (66)

1. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
2. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Purkerson ML, Tollefsen DM, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988; 81: 69-74
5. Purkerson ML, Joist JH, Greenberg JM et al. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thromb Res 1982; 26: 227-240
6. Ichikawa I, Yoshida Y, Fogo A et al. Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int 1988; 34: 638-644
7. Benck U, Haeckel S, Clorius JH et al. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-Angiotensin- aldosterone system. Clin J Am Soc Nephrol 2007; 2: 58-67
8. Olson JL. Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1984; 25: 376-382
9. Gambaro G, Venturini AP, Noonan DM et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806
10. Pesce C, Purkerson ML, Klahr S et al. Early changes in glomerular size and 3H-thymidine labeling index in controls and heparin-treated rats following subtotal nephrectomy. Kidney Int 1991; 43: 369-380
11. Diamond JR, Karnovsky MJ. Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Ren Physiol 1986; 9: 366-374
12. Coffey AK, Karnovsky MJ. Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 1985; 120: 248-255
13. Floege J, Eng E, Young BA et al. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 1993; 43: 369-380
14. Burg M, Ostendorf T, Mooney A et al. Treatment of experimental mesangioproliferative glomerulonephritis with non-Anticoagulant heparin: Therapeutic efficacy and safety. Lab Invest 1997; 76: 505-516
15. Peten EP, He CJ, Patel A et al. Non-Anticoagulant heparin suppresses all collagen mRNA and reduces laminin B1 mRNA expression in sclerotic glomeruli from mice transgenic for growth hormone (GH mice). J Am Soc Nephrol 1993; 4: 780
16. Gambaro G, Cavazzana AO, Luzi P et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-291
17. Oshima Y, Isogai S, Mogami K et al. Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. Diabetes Res Clin Pract 1994; 25: 83-89
18. Oturai PS, Rasch R, Hasselager E et al. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. APMIS 1996; 104: 259-264
19. Gambaro G, D'Angelo A, Del Prete D et al. Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Am J Nephrol 1999; 19: 530-534
20. Gambaro G, van der Woude FJ. Glycosaminoglycans: Use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11: 359-368
21. Caenazzo C, Garbisa S, Ceol M et al. Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: Molecular clues for its activity in nephropathy. Nephrol Dial Transplant 1995; 10: 175-184
22. Yung S, Chau MK, Zhang Q et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin- induced type I diabetic nephropathy. PLoS One 2013; 8: E54501
23. Ceol M, Nerlich A, Baggio B et al. Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996; 74: 484-495
24. Ceol M, Gambaro G, Sauer U et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of longterm diabetic rats. J Am Soc Nephrol 2000; 11: 2324-2336
25. Weigert C, Brodbeck K, Haring HU et al. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 2001; 60: 935-943
26. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: Implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008; 31(Suppl 2): S202-S207
27. Gil N, Goldberg R, Neuman T et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61: 208-216
28. van den Hoven MJ, Rops AL, Bakker MA et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70: 2100-2108
29. Masola V, Gambaro G, Tibaldi E et al. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 2011; 1813: 1475-1482
30. van den Hoven MJ, Rops AL, Vlodavsky I et al. Heparanase in glomerular diseases. Kidney Int 2007; 72: 543-548
31. Strutz FM. EMT and proteinuria as progression factors. Kidney Int 2009; 75: 475-481
32. Masola V, Gambaro G, Tibaldi E et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012; 287: 1478-1488
33. Masola V, Onisto M, Zaza G et al. A new mechanism of action of sulodexide in diabetic nephropathy: Inhibits heparanase-1 and prevents FGF-2- induced renal epithelial-mesenchymal transition. J Transl Med 2012; 10: 213
34. Pletinck A, Van Landschoot M, Steppan S et al. Oral supplementation with sulodexide inhibits neo-Angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant 2012; 27: 548-556
35. Webb LM, Ehrengruber MU, Clark-Lewis I et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993; 90: 7158-7162
36. Ceol M, Vianello D, Schleicher E et al. Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol 2003; 16: 210-218
37. Gambaro G, Skrha J, Ceriello A. Glycosaminoglycan therapy for long-term diabetic complications? Diabetologia 1998; 41: 975-979
38. Nader HB, Buonassisi V, Colburn P et al. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 1989; 140: 305-310
39. Broekhuizen LN, Lemkes BA, Mooij HL et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 2646-2655
40. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. DiabetesMetab 2000; 26(Suppl 4): 64-66
41. Gambaro G, Kinalska I, Oksa A et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-1625
42. Kristova V, Liskova S, Sotnikova R et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res 2008; 57: 491-494
43. Vasquez J, Mathison Y, Romero-Vecchione E et al. Effect of sulodexide on aortic vasodilation capacity and associated morphological changes in rats with streptozotocin-induced diabetes. Invest Clin 2010; 51: 467-477
44. Christensen PK, Hommel EE, Clausen P et al. Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney Int 1999; 56: 1517-1523
45. Drakeley SJ, Furness PN. Heparin inhibits the binding of immune complexes to cultured rat mesangial cells. Nephrol Dial Transplant 1994; 9: 1084-1089
46. van Bruggen MC, Walgreen B, Rijke TP et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 1996; 50: 1555-1564
47. Gambaro G, Kong NC. Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J Nephrol 2010; 23: 244-252
48. Cade JR, DeQuesada AM, Shires DL et al. The effect of long term high dose heparin treatment on the course of chronic proliferative glomerulonephritis. Nephron 1971; 8: 67-80
49. Morita Y, Makino H, Ota K et al. Beneficial effect of low molecular weight heparin ('fragmin') on proteinuria of proliferative glomerulonephritis. Clin Nephrol 1994; 42: 346-347
50. Rozita M, Md Shahrir MS, Loo CY et al. Glycosaminoglycans (sulodexide) for resistant heavy proteinuria of chronic glomerulonephritides. Nephrology 2008; 13(Suppl 1): A13
51. Bang K, Chin HJ, Chae DW et al. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Yonsei Med J 2011; 52: 588-594
52. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
53. Solini A, Carraro A, Barzon I et al. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diab Nutr Metab 1994; 7: 304-307
54. Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol 2006; 5: 211-222
55. Achour A, Kacem M, Dibej K et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18: 568-574
56. Blouza S, Dakhli S, Abid H et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010; 23: 415-424
57. Lewis EJ, Lewis JB, Greene T et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial. Am J Kidney Dis 2011; 58: 729-736
58. Packham DK, Wolfe R, Reutens AT et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 123-130
59. House AA, Weir MA. Sulodexide for diabetic nephropathy: Another one bites the dust. Am J Kidney Dis 2011; 58: 692-694
60. Coccheri S. Game not over for sulodexide. Am J Kidney Dis 2012; 59: 467
61. Gambaro G. Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis 2012; 60: 169-170
62. Gambaro G, Venturini AP, Chieco AO et al. Different heparin dosage are needed o ameliorate the evolution of different experimental nephropathies. Does this mean different heparin targets? Kidney Int Suppl 1995; 47: 689
63. Parving HH, Gall MA, Skott P et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762
64. Fioretto P, Mauer M, Brocco E et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-1576
65. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7: 140-145
66. Condorelli M, Chiariello M, Dagianti A et al. IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34